WEB SEARCH


TOP SELECTION

CONTACT US

info_demofinance@mynasdaq.it

DONATION

All profits of this web site are donated to charity 'the arsenal of peace'. VISIT THE WEBSITE

ADS

Complete financial analysis of GILEAD SCIENCES (GILD)

Name GILEAD SCIENCES
Year low 34.45
Year High 56.50
Symbol GILD
Last trade 50.47
Percentage change 0.00
Volume 0
Media Volume (3m) 7,626,530
PE Ratio 15.18
EPS 3.325
Market Cap 38222
Media fatt 8805
Trend fatt trend fatt graph for GILEAD SCIENCES
Media net income 2464
Trend net income trend net income for GILEAD SCIENCES
P / E P / E graph for GILEAD SCIENCES - 14 points 14
EPS EPS graph for GILEAD SCIENCES - 15 points 15
MARKET CAP / TOTAL REVENUE market  cap  /  total  revenue  graph for GILEAD SCIENCES - 0 points 0
TOT REV 1 / TOT REV 2 TOT REV 1 / TOT REV 2 graph for GILEAD SCIENCES - 6 points 6
NET INC 1 / NET INC 2 NET INC 1 / NET INC 2 graph for GILEAD SCIENCES - 3 points 3
MED NET INC / MED TOT REV MED NET INC / MED TOT REV graph for GILEAD SCIENCES - 13 points 13
NET INCOME / MARKET CAP NET  INCOME  /  MARKET  CAP graph for GILEAD SCIENCES - 3 points 3
TOTALREV1/TOTALREV3 totalRev1/totalRev3 graph for GILEAD SCIENCES - 6 points 6
NET INC1/NET INC3 net inc1/net inc3 graph for GILEAD SCIENCES - 0 points 0
TOT REV 2/ TOT REV 3 tot rev 2/ tot rev 3 graph for GILEAD SCIENCES - 4 points 4
NET INC 2 / NET INC 3 net inc 2 / net inc 3 graph for GILEAD SCIENCES - 4 points 4
. . graph for GILEAD SCIENCES - 0 points 0
MARKET CAP / NET TANGIBLE ASSETS MARKET CAP / NET TANGIBLE ASSETS graph for GILEAD SCIENCES - 0 points 0
MARK CAP/TOT STOCK EQ MARK CAP/TOT STOCK EQ graph for GILEAD SCIENCES - 0 points 0
MARKET CAP / TOT CURRENT ASSETS market cap / tot current assets graph for GILEAD SCIENCES - 0 points 0
TOT CURR ASSETS / TOT LIAB TOT CURR ASSETS / TOT LIAB graph for GILEAD SCIENCES - 3 points 3
. . graph for GILEAD SCIENCES - 0 points 0
SELL HOLD BUY SELL           HOLD          BUY graph for GILEAD SCIENCES - 0 points 0
SINTESE 71

GRAPHS

max price logarithm graph for GILEAD SCIENCES based on no conditions max volume linear graph for GILEAD SCIENCES based on no conditions

News

Gilead Sciences Inc.: Strong Growth At A Low Price (May 21 - reuters) Today's Bio Pharma ASCO Abstracts (May 17 - reuters) Five Highly Profitable Companies to Consider (May 17 - reuters) Idenix Will Move Up On Promising New Data In 2013 (May 11 - reuters) FDA panel recommends Gilead's Quad for HIV (May 11 - reuters) FDA Advisory Committee Supports Approval of Gilead`s Once-Daily Quad Single Tablet Regimen for HIV (May 11 - reuters) FDA Advisory Committee Supports Approval of Gilead`s Truvada® for Reducing the Risk of Acquiring HIV (May 11 - reuters) FDA panel backs Gilead's Truvada to prevent HIV (May 11 - reuters) Gilead's Quad HIV pill appears to be effective-FDA staff (May 09 - reuters) Gilead Sciences to Present at the Bank of America Merrill Lynch 2012 Health Care Conference on Wednesday, May 16 (May 08 - reuters) FDA staff: Gilead's Truvada may help prevent HIV infection (May 08 - reuters) Is Vertex Pharmaceuticals the Perfect Stock? (May 08 - reuters) Vertex Is the Next Gilead Sciences or Alexion (May 07 - reuters) Rolling Gilead Protected Covered Call For Additional Potential Profit (May 06 - reuters) Will Gilead Sciences Help You Retire Rich? (May 03 - reuters) Gilead Initiates Phase 3 Clinical Trial Evaluating GS-1101 for the Treatment of Chronic Lymphocytic Leukemia (May 02 - reuters) Gilead Sciences to Present at the Deutsche Bank 37th Annual Health Care Conference on Tuesday, May 8 (May 01 - reuters) Gilead Sciences Looks For Hepatitis C Cure (Apr 30 - reuters) Biotech Stock Mailbag: AVI, Aveo, Spectrum (Apr 27 - reuters) Gilead Sciences Management Discusses Q1 2012 Results - Earnings Call Transcript (Apr 27 - reuters) Gilead profit narrowly misses Street view (Apr 27 - reuters) Gilead Sciences Announces First Quarter 2012 Financial Results (Apr 26 - reuters) Vertex Hopes Two Cystic Fibrosis Drugs Better than One (Apr 24 - reuters) Biotech Stock Mailbag: Amarin (Apr 23 - reuters) Gilead, Bristol Shine at EASL Conference (Apr 21 - reuters) Celebrate the Hep C Wins, for Now (Apr 21 - reuters) Partner Up or Get Passed Up (Apr 20 - reuters) Gilead Sciences to Release First Quarter 2012 Financial Results on Thursday, April 26, 2012 (Apr 19 - reuters) Gilead, Bristol hepatitis C trial data impresses (Apr 19 - reuters) Thursday Shows Why Investors Own Biotech Stocks (Apr 19 - reuters) Gilead Sciences: S&P Intraday Gainer (Apr 19 - reuters) Gilead, Bristol Put Profits Ahead of Best Care for Hep C Patients (Apr 19 - reuters) Gilead Announces Early Sustained Virologic Response Rates for GS-7977 Plus Ribavirin in Genotype 1 Treatment-Naïve Hepatitis C Patients (Apr 19 - reuters) Gilead Announces Sustained Virologic Response Data for 12-Week Regimen of GS-7977 Plus Pegylated Interferon and Ribavirin in Genotype 1 Hepatitis C Patients (Apr 19 - reuters) Gilead, Bristol Hep C Drug Data Arrives at EASL (Apr 19 - reuters) Gilead hepatitis C drug proves itself in study (Apr 19 - reuters) Biotechnology And Drugs Stocks To Watch Ahead Of Earnings (Part 2) (Apr 18 - reuters) Gilead Sciences to Present New Hepatitis B and C Data at European Conference on Liver Disease This Week (Apr 18 - reuters) $100,000 Portfolio Update: 3 Buys And 2 Sells (Apr 17 - reuters) This Week's Bio-Pharma Stock Movers: The Hep-C Market. (Apr 16 - reuters) Biotech Stock Mailbag: All You Need to Know About Hep C Drugs (Apr 13 - reuters) Wednesday Options Recap (Apr 11 - reuters) Vertex: Watch New Hepatitis C Drug (Apr 11 - reuters) 6 Biotech Stocks With Huge Potential In May (Apr 11 - reuters) More Hep C Drug Abstracts Leak Ahead of EASL Confab (Apr 11 - reuters) Analyzing Last Week's Noteworthy Insider Trades In Healthcare (Apr 10 - reuters) GIlead And The Future of HIV Therapy (Apr 09 - reuters) Spectrum Pharma: The Growth Party is Over (Apr 09 - reuters) Winners, Losers From EASL Hep C Data Dump (Apr 04 - reuters) 3 Pharma Stocks With Various Degrees Of Upside, 1 To Surge (Apr 03 - reuters)

ADS

MY PORTFOLIO



GAIN vs LOSS


BEST vs WORST


SELECTION DIY

Market Cap
Last Trade
Gain/Loss
Webtech:
P / E
EPS
market cap / total revenue
TOT REV 1 / TOT REV 2
NET INC 1 / NET INC 2
MED NET INC / MED TOT REV
NET INCOME / MARKET CAP
totalRev1/totalRev3
net inc1/net inc3
tot rev 2/ tot rev 3
net inc 2 / net inc 3
.
MARKET CAP / NET TANGIBLE ASSETS
MARK CAP/TOT STOCK EQ
market cap / tot current assets
TOT CURR ASSETS / TOT LIAB
.
SELL HOLD BUY